A Financial Analyst Maintains That the Risk, Measured by the Variance

question 53

Multiple Choice

A financial analyst maintains that the risk, measured by the variance, of investing in emerging markets is more than 280(%) ². Data on 20 stocks from emerging markets revealed the following sample results: = 12.1% and s² = 361(%) ². Assume that the returns are normally distributed. Which of the following is the correct conclusion of the financial analyst's claim?

• A) Do not reject H₀. The financial analyst's claim is supported by the sample data at 1% significance level.
• B) Reject H₀. The financial analyst's claim is not supported by the sample data at 1% significance level.
• C) Do not reject H₀. The financial analyst's claim is not supported by the sample data at 1% significance level.
• D) Reject H₀. The financial analyst's claim is supported by the sample data at 1% significance level.

Understand the significance and formulation of gross profit in financial statements.

Understand the formulation of linear optimization models including objective functions, decision variables, and constraints.

Apply linear programming concepts to solve real-world optimization problems using tools like Excel Solver.

Identify and interpret essential components of linear optimization problems such as the objective function, constraints, and decision variables.

---

Definitions:

Registered Offering

A securities offering that has been registered with the Securities and Exchange Commission, making it available to the public.

Prospective Investors

Individuals or entities that are potentially interested in investing in a particular security, property, or business opportunity but have not yet committed to the investment.

Post-Effective Period

The time after a regulatory document, such as a registration statement with the SEC, becomes effective, allowing for the actual offer and sale of securities.

Waiting Period

A predetermined time frame during which a specific action or process must be paused or delayed before proceeding further, often used in regulatory, health, or insurance contexts.